Abstract
Introduction: The risk of cancer with the use of biologic agents in rheumatic diseases is still a matter of debate. Published data suggest that the extent of cancer risk might differ according to the type of cancer, and there is recent clinical evidence for a significant increased risk for skin cancer, including melanoma. In contrast with the extensive literature on cancer risk in rheumatoid arthritis, little has been reported on the development of malignancies in spondyloarthroparthies.
Case Presentation: We report the case of an otherwise healthy 31-year-old Italian woman with psoriasic arthritis who developed a melanoma of left third toe with metastatic involvement of regional lymphnodes after a 3-year treatment with the TNF-alpha inhibitor adalimumab.
Conclusion: This case illustrates the possibility of a causal relationship between TNF-alpha inhibitors and melanoma. We believe that vigilance should continue in patients treated with TNF-alpha blocking agents, until the question on the increased incidence of cancers, including skin cancers, associated with these drugs will be defined.
Keywords: Psoriatic arthritis, melanoma, adalimumab, rheumatic disease, spondyloarthroparthies, reginoal lymphnodes, TNF-alpha inhibiotrs, skin cancer
Current Drug Safety
Title: Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report
Volume: 6 Issue: 4
Author(s): Bianca Marasini, Luca Cozzaglio, Laura Belloli, Marco Massarotti, Nicola Ughi and Paolo Pedrazzoli
Affiliation:
Keywords: Psoriatic arthritis, melanoma, adalimumab, rheumatic disease, spondyloarthroparthies, reginoal lymphnodes, TNF-alpha inhibiotrs, skin cancer
Abstract: Introduction: The risk of cancer with the use of biologic agents in rheumatic diseases is still a matter of debate. Published data suggest that the extent of cancer risk might differ according to the type of cancer, and there is recent clinical evidence for a significant increased risk for skin cancer, including melanoma. In contrast with the extensive literature on cancer risk in rheumatoid arthritis, little has been reported on the development of malignancies in spondyloarthroparthies.
Case Presentation: We report the case of an otherwise healthy 31-year-old Italian woman with psoriasic arthritis who developed a melanoma of left third toe with metastatic involvement of regional lymphnodes after a 3-year treatment with the TNF-alpha inhibitor adalimumab.
Conclusion: This case illustrates the possibility of a causal relationship between TNF-alpha inhibitors and melanoma. We believe that vigilance should continue in patients treated with TNF-alpha blocking agents, until the question on the increased incidence of cancers, including skin cancers, associated with these drugs will be defined.
Export Options
About this article
Cite this article as:
Marasini Bianca, Cozzaglio Luca, Belloli Laura, Massarotti Marco, Ughi Nicola and Pedrazzoli Paolo, Metastatic Melanoma in a Young Woman Treated with TNF-Alpha Inhibitor for Psoriatic Arthritis: A Case Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280915
DOI https://dx.doi.org/10.2174/157488611798280915 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Classification Methods in Chemometrics
Current Analytical Chemistry Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Critical Review of Malondialdehyde Analysis in Biological Samples
Current Pharmaceutical Analysis Subject Index to Volume 9
Current Pharmaceutical Design The Impact of Docosahexaenoic Acid on Alzheimer’s Disease: Is There a Role of the Blood-Brain Barrier?
Current Clinical Pharmacology Vaccine Ingredients: Components that Influence Vaccine Efficacy
Mini-Reviews in Medicinal Chemistry State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Role of Early Growth Response-1 in the Development of Alcohol-Induced Steatosis
Current Molecular Pharmacology Dietary Antioxidants as Potential Pharmacological Agents for Ischemic Stroke
Current Medicinal Chemistry Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Pharmacological Strategies to Increase the Antitumor Activity of Methylating Agents
Current Medicinal Chemistry Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Box-Behnken Design Optimized TPGS Coated Bovine Serum Albumin Nanoparticles Loaded with Anastrozole
Current Drug Delivery Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Current Pharmaceutical Design Strategies for Integral Metabolism Profile of Multiple Compounds in Herbal Medicines: Pharmacokinetics, Metabolites Characterization and Metabolic Interactions
Current Drug Metabolism CARD Proteins as Therapeutic Targets in Cancer
Current Drug Targets